Statistics from Altmetric.com
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction: 3-year outcomes remain positive
The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction trial previously reported a reduction in major bleeding and net adverse clinical events in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention and treated with bivalirudin, as apposed to the use of heparin and a glycoprotein IIb/IIIa inhibitor. In addition, if eligible, patients were randomised to receive a paclitaxel-eluting or a bare-metal stent, and a reduction in target lesion revascularisation procedures was seen.
In this analysis, the authors report the final 3-year results from the trial. At 3 years, patients who received bivalirudin treatment had lower all-cause mortality (5.9% vs 7.7%; p=0.03), cardiac mortality (2.9% vs 5.1%; p=0.001), reinfarction (p=0.04) and major bleeding not related to bypass graft surgery (6.9% vs 10.5%; p=0.0001). No significant differences were seen in stent thrombosis, ischaemia-driven target vessel revascularisation or composite adverse events. However, stent thrombosis was high (>4.5%) in both groups. Overall, those receiving a paclitaxel-eluting stent had lower rates of ischaemia-driven target lesion revascularisation.
At 3-year follow-up, a mortality benefit was seen in patients …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.